Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22438551 | 1.00 | AR (0.38) | ARCTSKMEN1ALDH1A1MAPT | |
| SCHEMBL22438553 | 1.00 | AR (0.38) | ARCTSKMEN1ALDH1A1MAPT | |
| SCHEMBL19958775 | 0.80 | TSHR (0.44) | ARSETD7HSD11B1TSHRGPR119 | |
| SCHEMBL6441114 | 0.80 | TSHR (0.44) | ARSETD7HSD11B1TSHRGPR119 | |
| SCHEMBL6441117 | 0.80 | TSHR (0.44) | ARSETD7HSD11B1TSHRGPR119 | |
| SCHEMBL30900974 | 0.80 | TSHR (0.44) | ARSETD7HSD11B1TSHRGPR119 | |
| SCHEMBL6441115 | 0.80 | TSHR (0.44) | ARSETD7HSD11B1TSHRGPR119 | |
| SCHEMBL12489546 | 0.78 | SETD7 (0.39) | ARSETD7HSD11B1TSHRGPR119 | |
| SCHEMBL625040 | 0.78 | MAPT (0.43) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL34469108 | 0.77 | SETD7 (0.36) | ARSETD7HSD11B1TSHRGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079015-A1 | NOVEL DIHYDROISOXAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | NOVARTIS AG (CH) | 2021-03-18 | — | — | US | disclosed |
| US-20210079015-A1 | NOVEL DIHYDROISOXAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | NOVARTIS AG (CH) | 2021-03-18 | — | — | US | disclosed |
| EP-3710455-A1 | NOVEL DIHYDROISOXAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | Novartis AG (CH) | 2020-09-23 | — | — | EP | disclosed |
| CN-111315749-A | Novel dihydroisoxazole compounds and their use in the treatment of hepatitis b | 诺华股份有限公司 | 2020-06-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079015-A1 | NOVEL DIHYDROISOXAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | XDH, SLC10A1, RORB | AR 3283/4885CTSK 2933/4885MEN1 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.